A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 263
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : HE4
Long Form : human epididymis protein 4
No. Year Title Co-occurring Abbreviation
2019 C60 Mediated Ion Pair Interaction for Label-free Electrochemical Immunosensing with NAA Nanochannels. NAA
2019 Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis. DOR, EC, NLR, PLR, SROC
2019 CYFRA 21-1 and Placental Growth Factor as Screening Markers for Endometriosis. CA, NPV, PPV, ROMA
2019 Development of a multiplexed giant magnetoresistive biosensor array prototype to quantify ovarian cancer biomarkers. GMR, IL-6, LOD
2019 Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels. CA125
2019 Epithelial cell adhesion molecule (EpCAM) from pleural fluid cell lysates is a highly accurate diagnostic biomarker of adenocarcinomatous effusions. CL, cl, CL4, EpCAM, PE, PF
2019 Human epididymis protein 4 quantification and interaction network analysis in seminal plasma. ---
2019 Hypoxia-Induced Upregulation of HE4 Is Responsible for Resistance to Radiation Therapy of Gastric Cancer. ChIP, GC, HIF1alpha
2019 Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. ADC, AUC, CI, NSCLC, ROC
10  2019 RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: A prospective population-based study. ---
11  2019 The role of human epididymis protein 4 as a biomarker in gynecologic malignancies. EC, OC
12  2019 [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. AAbs, CPH-I, PCI
13  2018 Adnexal mass with extremely high levels of CA-125 and CA19-9 but normal Human Epididymis Protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA): Endometriosis or ovarian malignancy? A case report. CA, ROMA
14  2018 Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer. EOC
15  2018 Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. CA125, CA19-9, CEA
16  2018 Diagnostic value of HE4 in ovarian cancer: A meta-analysis. CI, DOR, HSROC, NLR, PLR, SROC
17  2018 Effects of different degrees of depression on inflammatory response and immune function in patients with ovarian cancer. BDI, FIGO, IGF-I
18  2018 Electrochemical quantum dots-based magneto-immunoassay for detection of HE4 protein on metal film-modified screen-printed carbon electrodes. SPCE
19  2018 Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy. AUC, CA125, ROC, ROMA
20  2018 Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125. PPV, TTR
21  2018 Falsely elevated human epididymis protein 4 results and Risk of Ovarian Malignancy Algorithm in polymorbid women after solid organ transplantation: A pilot and case-control study. ROMA
22  2018 HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction. eIF3a, ICS, OS, ROC, SCS, TS
23  2018 HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells. DUSP6, IFN, IL, OPN, PBMCs, PFS
24  2018 Highly elevated human epididymis protein 4 (HE4) following endometrioma rupture: a case report. ---
25  2018 Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment. BMI, CF, CRP, ROC-AUC
26  2018 Human epididymis protein 4 concentration is not associated with liver fibrosis and cirrhosis in a case control study. CLD, CP, LSM
27  2018 Human epididymis protein 4 in endometrial cancer: A meta-analysis. AUC, DOR, EC, NLR, PLR, SEN, SPE
28  2018 Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers. CCL18, IPF, SP
29  2018 Increased HE4 mRNA Expression Correlates with High Level Of eIF3a mRNA And Better Survival in Women with Epithelial Ovarian Cancer. eIF3a, EOC, IHC, OS
30  2018 Making new biomarkers a reality: the case of serum human epididymis protein 4. CA125, OVCA
31  2018 Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women. CA125, ECLIA, RIs, ROMA
32  2018 MicroRNA-149 sensitizes colorectal cancer to radiotherapy by downregulating human epididymis protein 4. CRC
33  2018 Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant. HGSC
34  2018 Novel heart failure biomarkers: why do we fail to exploit their potential? ADM, Gal-3, GDF15, H-FABP, HF, hsTn, IGFBP-7, IL-6, miRNAs, PCT, sCD146, sST2
35  2018 Preparation and characterization of a high-affinity monoclonal antibody against human epididymis protein-4. DSC
36  2018 Prognostic value of HE4 in patients with ovarian cancer. CI, HR, OC, OS, PFS
37  2018 Quantitative screening of serum protein biomarkers by reverse phase protein arrays. AFP, B2M, CA15-3, CEA, GDF15, GP73, HCC, IGFBP-2, LDA, LR, OPN, RF, RPPAs, SVM
38  2018 Safety and Outcome Measures of First-in-Human Intraperitoneal alpha Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. CA 72-4, CEA, i.p, IL-6, SAA, TAG-72
39  2018 Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus: A prospective cohort study. ESR, LN, ROC, SLE, SLEDAI
40  2018 Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up. CA125, OC, RCV
41  2018 Serum levels of human epididymis protein 4 are more stable than cancer antigen 125 in early and mid-term pregnancy. CA125, TA
42  2018 Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers. CA125, EOCs, NC, ROC-AUC, ROMA
43  2018 Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. EOC, ROMA
44  2018 The Clearance of Serum Human Epididymis Protein 4 Following Primary Cytoreductive Surgery for Ovarian Carcinoma. ---
45  2018 The clinical significance of DJ-1 and HE4 in patients with endometrial cancer. EC, HC, ROC
46  2018 The diagnostic value of human epididymis protein 4 as a novel biomarker in patients with renal dysfunction. eGFR
47  2018 The diagnostic, prediction of postoperative recurrence and prognostic value of HE4 in epithelial ovarian cancer. EOC, PFS
48  2018 The fabrication of magnetic particle-based chemiluminescence immunoassay for human epididymis protein-4 detection in ovarian cancer. ELISA, MPCLIA
49  2018 Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer. AUC, CgA, LC, NSE, ProGRP, SCC-Ag
50  2018 Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery. CA125
51  2017 Aberrant MicroRNA Expression in Patients With Endometrial Cancer. CA125, EC, miRNA
52  2017 Bcl-3 is a novel biomarker of renal fibrosis in chronic kidney disease. CKD, UUO
53  2017 CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. CA125, CEA, DFS, NSCLC, NSE
54  2017 Clinical Usefulness of Human Epididymis Protein 4 in Lung Cancer. TNM
55  2017 Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer. EOC, ER, PI, RI, TIC, TVCEUS
56  2017 Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City. CA125
57  2017 Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients. EOC, NPV, PPV, ROMA
58  2017 Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study. CA125, NRI, ROMA, SA, SR, TVS
59  2017 Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women. AUC, CA125, CPH-I, EOC, Mi, RMI, ROMA
60  2017 Diagnostic Performance of Serum Human Epididymis Protein 4 in Endometrial Carcinoma: A Pilot Study. AUC, EC, ELISA, ROC
61  2017 Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay. AUC, CA125, OC
62  2017 Diagnostic value of urinary-to-serum human epididymis protein 4 ratio in ovarian cancer. CKD, HC, OC, R-HE4, ROC, S-HE4, U-HE4
63  2017 HE4 expression in lung cancer, a meta-analysis. CIs, HRs, OS
64  2017 HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure. CHF, HF, PREVEND, VitD-CHF
65  2017 Human Epididymis Protein 4 as a Potential Biomarker of Chronic Kidney Disease in Female Patients With Normal Ovarian Function. CKD, OR
66  2017 Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Mullerian origin from gastrointestinal cancer. EOC, PAX8
67  2017 Human epididymis protein 4 may not be a reliable screening biomarker for detecting lung carcinoma patients. AC, NSCLC, SCLC
68  2017 Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracelluar Matrix. rHE4, ROMA
69  2017 Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses? AUC, CA125, OC, RMI, ROMA, US
70  2017 Molecularly Imprinted Photo-electrochemical Sensor for Human Epididymis Protein 4 Based on Polymerized Ionic Liquid Hydrogel and Gold Nanoparticle/ZnCdHgSe Quantum Dots Composite Film. ---
71  2017 New biomarkers in epithelial ovarian cancer: needed or redundant? ---
72  2017 Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: A multicenter prospective study. CA125, ROMA
73  2017 Potential association between elevated serum human epididymis protein 4 and renal fibrosis: A systemic review and meta-analysis. MMP2, MMP9, SMD
74  2017 Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study. MI
75  2017 Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer. CA125, TK1
76  2017 Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer. EGF
77  2017 Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors. AGCTs, AMH, AUC, CA125, ENDO, EOC, ROC
78  2017 Serum human epididymis protein 4 levels in colorectal cancer patients. CA19-9, CEA, CRC
79  2017 The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. CT, NACT, RT
80  2017 Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. OC
81  2017 Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study. CI
82  2017 [Ascites May Provide Useful Information for Diagnosis of Ovarian Cancer]. CA125, CAE
83  2017 [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer]. CEA, FIGO, HGSOC, NGS, STM
84  2016 A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women. B7-H4, CA125, EOC, suPAR
85  2016 A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study. ---
86  2016 A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study. CA125, CONATS, PDS
87  2016 Analysis of falsely elevated risk of ovarian malignancy algorithm in women with ovarian endometrioma. ROMA
88  2016 Analysis of the gene expression profile in response to human epididymis protein 4 in epithelial ovarian cancer cells. DEGs
89  2016 Association of Serum HE4 with Primary Tumor Diameter and Depth of Myometrial Invasion in Endometrial Cancer Patients at Rajavithi Hospital. CA125, DMI, EC, PTD
90  2016 Bone Metabolism of the Patient with a Malignant Melanoma during the Entry Examination and the Check-up of Whole-body Bone Scintigraphy. OC
91  2016 CA125 and HE4: Measurement Tools for Ovarian Cancer. CA125
92  2016 Comparison of Diagnostic Accuracies of Serum HE-4 Levels and 3D Power Doppler Angiography Parameters between Benign Endometrial Pathologies and Endometrial Cancer. AUC, FI, NPV, PPV, VFI, VOCAL
93  2016 Comparison of HE4 and CA125 levels in women withbenigngynecologicdisorders : Does age or menopausal status matter? CA125
94  2016 Comparison of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 as Markers in Endometrial Cancer: A Meta-Analysis. CA125, EC
95  2016 Cystatin C provides a better estimate of the effect of glomerular filtration rate on serum human epididymis protein 4 concentrations. CKD-EPI, Cr, CysC, GFR
96  2016 Detection of Human Epididymis Protein 4 (HE4) in Human Serum Samples Using a Specific Monoclonal Antibody-Based Sandwich Enzyme-Linked Immunosorbent Assay (ELISA). ELISA, FDA
97  2016 Diagnostic Accuracy and Optimal Cutoff Value of Serum HE4 to Predict Ovarian Cancer in Thai Women with Pelvic Masses. OCs, ROC-AUC
98  2016 Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma. CA125, PFTC
99  2016 Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125. AUCs, CA125, NPV, PPV, ROMA
100  2016 Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer. CA125, EOC